Transmission-dependent tolerance to multiclonal Plasmodium falciparum infection.
Whether the number of concurrent clones in asymptomatic Plasmodium falciparum infections reflects the degree of host protection was investigated in children living in areas with different levels of transmission on the coast of Kenya. The number of concurrent clones was determined on the basis of polymorphism in msp2, which encodes the vaccine candidate antigen merozoite surface protein 2. In a low-transmission area, most children had monoclonal infections, and diversity did not predict a risk of clinical malaria. In an area of moderate transmission, asymptomatic infections with 2 clones were, compared with 1 clone, associated with an increased risk of subsequent malaria. In a comparative assessment in a high-transmission area in Tanzania, multiclonal infections conferred a reduced risk. The different nonlinear associations between the number of clones and malaria morbidity suggest that levels of tolerance to multiclonal infections are transmission dependent as a result of cumulative exposure to antigenically diverse P. falciparum infections.
Färnert
Anna
A
Infectious Diseases Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden. anna.farnert@ki.se
Williams
Thomas N
TN
Mwangi
Tabitha W
TW
Ehlin
Anna
A
Fegan
Greg
G
Macharia
Alex
A
Lowe
Brett S
BS
Montgomery
Scott M
SM
Marsh
Kevin
K
D000818:Animals; D000953:Antigens, Protozoan / Q000235:genetics / Q000378:metabolism; D002648:Child; D002675:Child, Preschool; D005786:Gene Expression Regulation; D005838:Genotype; D006801:Humans; D007223:Infant; D007630:Kenya / Q000453:epidemiology; D016778:Malaria, Falciparum / Q000453:epidemiology / Q000276:immunology* / Q000469:parasitology*; D010963:Plasmodium falciparum / Q000145:classification / Q000235:genetics* / Q000276:immunology*; D015800:Protozoan Proteins / Q000235:genetics / Q000378:metabolism; D013997:Time Factors
D000953:Antigens, Protozoan; D015800:Protozoan Proteins; C065974:merozoite surface protein 2, Plasmodium
Microbes Infect. 2007 Jan;9(1):103-10
17194613
Trends Parasitol. 2008 Aug;24(8):340-4
18617441
Am J Trop Med Hyg. 1996 Jun;54(6):632-43
8686784
Trans R Soc Trop Med Hyg. 2004 Dec;98(12):687-94
15485698
Trop Med Int Health. 2003 Jan;8(1):3-11
12535242
Am J Trop Med Hyg. 1997 Feb;56(2):141-7
9080871
J Infect Dis. 1997 Apr;175(4):921-6
9086150
J Infect Dis. 1999 Apr;179(4):989-95
10068596
Am J Trop Med Hyg. 2002 Jun;66(6):653-8
12224569
Vaccine. 2006 May 8;24(19):4233-46
16111789
Infect Immun. 2001 Dec;69(12):7783-92
11705960
Trans R Soc Trop Med Hyg. 1999 Feb;93 Suppl 1:15-20
10450421
Trans R Soc Trop Med Hyg. 1999 Feb;93 Suppl 1:29-34
10450423
Trans R Soc Trop Med Hyg. 1999 Feb;93 Suppl 1:21-8
10450422
Trans R Soc Trop Med Hyg. 2001 Mar-Apr;95(2):143-8
11355544
Parasitology. 1994 Nov;109 ( Pt 4):413-21
7800409
Am J Trop Med Hyg. 1995 Mar;52(3):201-6
7694959
Parasitology. 2001 Aug;123(Pt 2):113-23
11510676
Am J Trop Med Hyg. 1995 Jan;52(1):81-8
7856831
Parasitology. 1998 Jun;116 ( Pt 6):501-10
9651932
Int J Parasitol. 2004 Jul;34(8):935-42
15217732
Trans R Soc Trop Med Hyg. 1997 Sep-Oct;91(5):602-5
9463681
J Infect Dis. 2005 Jun 1;191(11):1932-9
15871128
Lancet. 1997 Jun 7;349(9066):1650-4
9186382
Acta Trop. 2001 Feb 23;78(2):155-62
11230825
Ann Trop Med Parasitol. 2001 Mar;95(2):117-32
11299119
Trans R Soc Trop Med Hyg. 1999 Feb;93 Suppl 1:47-51
10450426
Trans R Soc Trop Med Hyg. 1999 Jul-Aug;93(4):369-74
10674079
Trans R Soc Trop Med Hyg. 1998 Nov-Dec;92(6):580-5
10326095
Am J Trop Med Hyg. 2002 Dec;67(6):604-10
12518850
Am J Trop Med Hyg. 2003 Jun;68(6):734-42
12887036